HIGHBuilt-in & outside partyProduct / Revenue mix
single approved product
“10-K Item 1A: 'we have only one product based on RNAi and our delivery technologies approved in November 2025'”
ARWR · Concentration risk · 10-K extracted
Arrowhead Pharmaceuticals (ARWR) concentration risks
Updated
The most significant concentration Arrowhead Pharmaceuticals discloses is single approved product, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Arrowhead Pharmaceuticals’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH1
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partySupplier
third-party manufacturers
“10-K Item 1A: 'must rely on third-party manufacturers to manufacture certain of our clinical supplies and our commercial products'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile is defined by two related disclosures: a high-share dependency on its sole approved product and a medium-share reliance on third-party manufacturers for both clinical and commercial supply. The company has only one product based on its RNAi and delivery technologies that received approval in November 2025, a high-share product concentration with a mixed character — structural in that the entire commercial strategy is organized around this platform and its derivatives, but dependency-like because there is no revenue diversification across multiple approved assets. A clinical safety signal, regulatory action, or competitive displacement of this single approved product would directly impair the company's financial position, as no other commercial revenue source exists to partially offset the impact. Complementing the product concentration is a medium-share manufacturing dependency: the company must rely on third-party manufacturers to produce certain clinical supplies and commercial products. The company does not own all of its own manufacturing infrastructure, which means that capacity availability, quality control, and relationship continuity with contract manufacturers are operational dependencies that sit outside the company's direct control. Taken together, the profile describes an early-commercial-stage biopharmaceutical company with one approved product that it manufactures through external partners. The approved product concentration is the most consequential exposure — it defines the entire revenue profile — while the manufacturing dependency adds an operational layer. Monitoring the commercialization trajectory of the approved product alongside contract manufacturer performance are the central watch items.
For the engine’s reasoning on ARWR’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| ARWR● | Arrowhead Pharmaceuticals, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.